Research Studentship - Colin Maslink

Colin Maslink is a Medical Student at the University of Toronto.

Colin's project has been generously supported by the Turek Family

About my experience

Receiving this Studentship has had a profound impact on me, both personally and professionally. Firstly, I have been able to gain valuable lab experience and develop necessary research skills that I can carry forward in a career as a clinician-scientist. This includes learning the rationale and protocol of different molecular techniques, such as Western blots, genotyping, and RNA extractions, as well as learning the broader theoretical concepts behind developing models and experiments for preclinical neuro-oncology research. I’ve also been able to observe how much thoughtfulness, patience, and collaboration goes into designing and performing this research.

Final Report

During the past two summers, we have made significant progress in our evaluation of MRI-guided focused ultrasound (MRIgFUS) as a potential treatment for diffuse intrinsic pontine glioma (DIPG).

Firstly, we have demonstrated that MRIgFUS is a safe and well-tolerated treatment when used to achieve blood-brain barrier (BBB) disruption in the brainstem of healthy rats. No cardiorespiratory or neurological deficits were noted and no microscopic damage to the brainstem was found. 

Next, we have observed that doxorubicin, when compared to other traditional chemotherapeutics, is the most cytotoxic agent against our in vitro DIPG cell lines.  We have also shown that with MRIgFUS, we can deliver a 40 fold greater quantity of doxorubicin into the brainstem compared to doxorubicin administration without MRIgFUS. Thus, doxorubicin is a very promising chemotherapeutic to use in combination with MRIgFUS.

Project Update

To date, we have evaluated the safety of MRI-guided focused ultrasound (MRIgFUS) with microbubble administration in a rat model. This is essential to do before testing treatment with a chemotherapeutic agent in order to verify that the MRIgFUS procedure itself, when targeted at the delicate and vital brainstem, is not detrimental. Safety testing was performed by monitoring cardiorespiratory vital signs before, during, and after treatment, as well as motor function before and after treatment. Preliminary data analysis suggests that MRIgFUS with microbubble treatment is a safe procedure in this model. 

In addition, in-vitro experiments utilizing glioma cell lines have been performed to elucidate the most effective chemotherapeutic treatment to combine with the MRIgFUS procedure. For instance, a Western blot assay was performed to demonstrate that treating glioma cells with cisplatin conjugated to a gold nanoparticle (GNP) caused the most genetic damage to glioma cells and, thus, is the more efficacious treatment. Moving forward, we will deliver GNP-conjugated cisplatin as a chemotherapeutic agent for testing the efficacy of MRIgFUS treatment. 

Finally, I personally have been able to learn several techniques central to the field of brain tumour research, such as Western blots, immunofluorescence assays, genotyping, and basic cell culture techniques, that can be utilized in our future plans of testing the efficacy of GNP-conjugated cisplatin with MRIgFUS as a treatment for DIPG.

About the Research

Project title: "Targeted therapeutic disruption of the blood-brain barrier in childhood brainstem cancers”
 
Diffuse intrinsic pontine glioma (DIPG), a tumour that involves the brainstem and occurs almost exclusively in children ages 5-9, is one of the most devastating tumours with a near 100% fatality rate within 2 years of diagnosis. Currently, there are poor treatment options due to the impermeable blood-brain barrier (BBB) that prevents chemotherapeutic drugs from entering the brain. One technique, MRI-guided focused ultrasound (MRIgFUS), has been shown to transiently disrupt the BBB, increasing the delivery of drugs to brain tumours. 
 
The purpose of our project is to determine the effectiveness of MRIgFUS in aiding the delivery of chemotherapeutic drugs (e.g. panobinostat) to brainstem tumours, using a preclinical model of DIPG generated through transplantation of human glioma cells into mice. It is hypothesized that this technique will offer temporary disruption of the BBB, allowing focused delivery of chemotherapeutics to the brainstem. Given that MRIgFUS is already used in patients for other diseases, it is expected that enhanced drug delivery using MRIgFUS could be rapidly translated to the clinic, leading to new clinical trials aimed to improve the outcome of children suffering from DIPG and other tumours.

About Colin, in his own words...

Colin, Research Student

For me, research has always been a life-altering experience. An early experience working in a neuroscience lab lead to further summers in the lab, which lead to pursuing volunteer experiences with children experiencing neurological conditions, and ultimately culminated in entering medical school with a clinical interest in the neurosciences. 
 
Similarly, being awarded a Brain Tumour Research Studentship means much more than just having the opportunity to pursue brain tumour research, an interest that stems from my past research, the inspiration I’ve felt volunteering with affected children, and the emotional drive of seeing the toll cancer can take. It also presents an opportunity to develop research skills and experiences that I can carry forward in a career as a brain tumour researcher and beyond. Much bigger than that, it presents an opportunity to join the many researchers who are helping to impact and alter the lives of those suffering from brain tumours. 
 
Words cannot express how thankful I am to the Turek family and to the Foundation for this opportunity to explore new treatments for pediatric brain tumours, to impact the lives of those affected, to grow as a brain tumour researcher and to join the many scientists in the endeavour of creating hope.

<Back to all Brain Tumour Research Studentships

 

Share This

Featured Story

Make every brain tumour count

Stephanie, a 38-year-old mother of twins has been diagnosed with an extremely rare and inoperable brain tumour - a rosette-forming glioneuronal tumour, a type of tumour that little is known about and cannot be removed due to its location in her brain. This reality does not stop Stephanie from her tireless efforts to reduce the stigma of having a brain tumour. Learn why Stephanie is urging all Canadians to make every brain tumour count.

Learn more

Spotlight

Piper's Story: a dream more precious than Olympic gold

Hi, I am Piper Gilles. You may know me as a world-famous ice dancer. I competed in the PyeongChang 2018 Olympic Winter Games. I am a 7...

Learn more

Doug's Adventure

I am Doug, I have brain cancer; I am told it is terminal, but the “good” kind of terminal. I can assure you that receiving that news...

Learn more

Upcoming Events

  • 26/Aug/2019: Greater Sudbury Support Group: Meets at The Parkside Centre, 140 Durham Street, Sudbury, Ontario... Learn more >
  • 27/Aug/2019: Webinar: Pituitary Tumours – Treatment & Management : Free webinar. Please register to join.... Learn more >
  • 28/Aug/2019: Toronto Support Group: Meets at Wellspring Westerkirk House at Sunnybrook, Toronto, ON... Learn more >
  • 01/Sep/2019: C Cup Classic 2019: Rocky Mountain Turf Club, Lethbridge, AB and Century Downs Racetrack &... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2019 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001